9.11 0.00 (0.00%)
After hours: 7:52PM EDT
|Bid||9.09 x 46000|
|Ask||9.11 x 27000|
|Day's Range||8.96 - 9.17|
|52 Week Range||4.05 - 12.52|
|Beta (3Y Monthly)||2.80|
|PE Ratio (TTM)||42.18|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER , April 24, 2019 /CNW/ - Hempco Food and Fiber Inc. (HEMP.V) ("Hempco" or the "Company") is pleased to announce Q2 2019 results for the period ending February 28, 2019. WKN: A1C4WM) Acquisition: On April 16, 2019 , Aurora Cannabis Inc. (Aurora) and Hempco announced the companies had entered into a binding letter agreement (the "Letter Agreement") for Aurora to acquire all of the remaining issued and outstanding common shares of Hempco ("Hempco Shares") not already owned.
Investors never like to hear that a company could take actions that result in possible dilution. But that's exactly what Aurora Cannabis (ACB) investors heard this afternoon.The Canadian medical marijuana maker came out with a shelf registration statement, notifying the securities regulators in Canada and the US that it would consider selling up to US$750 million in newly issued common stock as needed over a specified amount of time. If all shares under the new shelf registration are sold, it would result in significant dilution.Aurora shares closed today at $9.07, down $0.11 or -1.20%Executive Chairman Michael Singer commented, "Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global expansion and partnering strategy [...] With our recent listing on the NYSE, our successful financing in January 2019 led by U.S. institutional investors, and as we work with Nelson Peltz to explore potential partnership opportunities, this filing is a natural evolution for our company as we rapidly mature into a global and profitable organization."These types of filings aren’t uncommon. The ability to fund operations with share offerings is actually one of the main reasons to become a publicly traded company in the first place. The silver lining, if there is one, is that Aurora does appear to be making headway. But today’s news serves as a reminder that obtaining the necessary capital to fund development won’t always be done in a shareholder-friendly manner.Overall, investors are likely concerned that new diluted ownership from equity financing would increase the risk profile of ACB. However, TipRanks reveals the cannabis stock as one drawing bullish attention on Wall Street. Out of 8 analysts polled in the last 3 months, 6 rate ACB stock a Buy, while 2 remain sidelined with a Hold rating.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on ACB: * Aurora Cannabis (ACB) Stock Ready to Rumble * Analyst Commends Cannabis Stock Aurora for Peltz Pick * Can One Man Make a Difference for Aurora Cannabis (ACB) Stock? * Breaking Down the Aurora Cannabis (ACB) Investment Portfolio: Choom Holdings More recent articles from Smarter Analyst: * Cannabis Stock Health & Recreation (HRVSF) Is Very Appealing Based on Long-Term Bullish Fundamentals * Cannabis Stock Canopy Growth (CGC) Stands to Gain from Potential Legalization in the US * Cowen Counts the Points in Aurora Cannabis (ACB) Stock's Favor * With Two Days to Go Before Amazon (AMZN) Earnings, this Top Analyst Weighs in on the Stock
Aurora Cannabis Inc (NYSE: ACB) is off to a hot start to 2019, but the stock is still trading well below its 2018 highs. Aurora shares have been trapped in a narrow horizontal trading range between around $8.50 and $9.25 since mid-March. For a stock with a history of extreme volatility, Aurora has been stuck in an extended low-volatility consolidation period.
CORAL GABLES, FL / ACCESSWIRE / April 24, 2019 / Marijuana Stocks took a brief but much-needed breather on April 23, 2019. This trend has been clearly observed from some of the key players in the cannabis industry. Today we are highlighting: Aurora Cannabis (ACB), Canopy Growth (CGC) (TSX:WEED.TO), Aphria (APHA), Innovative Properties Inc. d/b/a Nabis Holdings (INNPF) (NAB.CN).
Last week, a blockbuster story for marijuana stocks -- one of the biggest in years -- slipped by a lot of investors. It was in the news, but most investors don't know the industry well enough or the players involved to grasp its huge significance. To them, it was just another headline.Not to me. I've been waiting years to write this story, and now the final chapter is taking shape.I'm extremely bullish on the once-in-a-lifetime opportunity to build wealth in marijuana stocks. There was a time when other investors laughed at me because of it. Not anymore.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBasically, the biggest marijuana company in the world and some of the most connected people in the world all but told us that U.S. marijuana legalization is coming… and perhaps sooner than expected. What's the Big Deal?Cannabis giant Canopy Growth (NYSE:CGC), which is based in Canada, confirmed last week that it plans to enter the U.S. market. The $16.5 billion company made an offer to buy U.S.-based Acreage Holdings (OTCMKTS:ACRGF).At first glance, that doesn't sound all that important. But remember: Marijuana is legal in Canada. It is not in the United States, at least on the federal level. * 10 Stocks to Sell Before They Give Back 2019 Gains In fact, any company that touches the marijuana plant in the United States cannot list on a major stock exchange -- the New York Stock Exchange (NYSE), NASDAQ, even the Toronto Stock Exchange (TSX).Well, guess what? Canopy already trades on the NYSE and TSX. If it were to enter the U.S. marijuana market right now, it would be forced to delist from both and move down to a lesser known, less liquid exchange.There is no way the company would let that happen.So what prompted Canopy to prepare to enter the U.S. now? Why not next month? Next year? Why not wait until after marijuana legalization?Two reasons. One, Canopy wants to be ready to capitalize on what will instantly become the largest marijuana market in the world the moment it becomes legal.And two, Canopy all but knows -- or is at least extremely confident -- that legalization is right around the corner.Management didn't say that outright. I wouldn't expect them to. But I believe it to be true because of three very important people on the board of Acreage Holdings: * Former U.S. Speaker of the House John Boehner, * Former Canadian Prime Minister Brian Mulroney, * And former Massachusetts Governor and current Republican presidential candidate William Weld.Among those three gentlemen, there is undoubtedly insight into marijuana's future that you and I are not yet privy to.But if we know the industry and the players involved, we can connect the dots. These two companies have access to and insight from three of the most politically connected men in the world. They decided it was time to make a deal.If Canopy believed U.S. legalization was still years away, there would be absolutely no reason to buy the rights to Acreage yet.Last week's announcement is like knowing the score of a game before it starts. Marijuana stocks are already on the move, but you still have time to position yourself to make a lot of money as legalization sweeps the globe and the industry grows many times over. Now is the TimeInstead of buying Acreage outright today, Canopy wisely bought the "rights" to purchase the company when marijuana becomes fully legal in the United States. That last part is the key. And Canopy wouldn't do that if legalization were still years away.When marijuana does become legal, Canopy will pay $3.4 billion, a 42% premium over Acreage's average value the last month. The deal is mostly stock, which means Canopy still has more than enough cash to make similar deals.Canopy Growth is not just any marijuana company. It is the biggest cannabis company in the world, so deals like this speak volumes. Canopy's $16.5 billion market cap is nearly 80% above its closest competitor, Aurora Cannabis (NYSE:ACB), which his valued at $9.2 billion.Last June, Canopy was the first of the marijuana stocks I've recommended to my Investment Opportunities readers. We're up 58% since then, capitalizing on the stock's nearly 80% jump in 2019. It is above my recommended buy limit, but it is a stock every cannabis investor should try to own at the right price.In the wake of the big news, we will be adding fresh stocks in position to benefit from the coming U.S. marijuana legalization. In the meantime, there are other great buys with huge potential, from growers to suppliers to real estate companies to IPOs and more.Some of the absolute best opportunities are in smaller companies that are about to explode -- possibly into the next Canopy Growth or Aurora Cannabis. In fact, one tiny company I recommend even has interesting connections to Canopy Growth.I am more excited than ever about the opportunity to make life-changing gains as the marijuana industry grows exponentially in the coming years. Now is the time to act. A Chance for Life-Changing GainsThat tiny company I mentioned is a unique type of investment among red-hot marijuana stocks.As the cannabis industry grows exponentially in the coming years, it could realistically multiply your money several times over… if you take part soon -- I'd say no later than April 25.The company is part of a phenomenon that has only occurred a small handful of times in the past few decades -- in other industries. But on many occasions, it's resulted in an explosion of wealth so incredible, the numbers almost seem made up.The first time we saw it was in 1983, when it returned early investors as much as 45,300% gains!Incredibly, there is that opportunity once again, right now… in the booming marijuana market.This is so important that I put together a presentation with all of the details on this rare opportunity and why you need to act now. Click here to learn all about it.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post A Game-Changing Moment for Marijuana Stocks Just Got Closer appeared first on InvestorPlace.
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Cannabis stocks were mostly lower Tuesday, as investors took a breather after Monday’s gains to lock in profits and await the next developments in the sector.
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.05, marking a -1.95% move from the previous day.
After looking like they were set to break down, shares of Canopy Growth (NYSE:CGC) have been surging over the past few trading sessions. As such, CGC stock is up almost 20% over the past five days and on the cusp of breakout territory, with higher prices on many bulls' radar.Source: Shutterstock What so suddenly has CGC stock back in investors' good graces? To be fair, the company didn't really do anything to fall out of their good graces. Rather, it was simply the fading momentum of marijuana stocks at the time.However, momentum was restored in Canopy Growth stock once reports began circulating about its intention to purchase Acreage Holdings (OTCMKTS:ACRGF). The deal is for $300 million in cash and swelled to $3.4 billion once Canopy included 0.58 shares for each subordinate voting share of ACRGF.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Digital Ad Stocks That Deserve Your Attention Right Now Investors are viewing the deal favorably as Acreage Holdings has exposure in 20 different U.S. states. In other words, it's Canopy's way of pushing into the U.S. This comes as it focuses on its future and growing its market share. At the end of the day, market share is a very important component to the cannabis industry. That's one reason why Canopy is considered the leader of this group. Trading CGC StockThe charts for CGC stock look a little busy here, but each level is relevant. The recent action has shown a return of momentum to Canopy Growth stock, but also names like Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON), among others. It's even given a boost to names like Constellation Brands (NYSE:STZ), which has a near-40% stakes in CGC.That momentum has carried CGC stock into a potentially large breakout area over $48. Where can it go? One analyst says Canopy could run to $72, implying about 90% upside from current levels. Can it actually get there?$48 is the first key test. In the last three trading sessions, CGC stock reclaimed its 20-day and 50-day moving averages as well as prior uptrend support (blue line No. 1). It also cleared prior downtrend resistance (blue line No. 2) and key resistance at $48. Now hovering near $48.25, it's important that CGC stock doesn't give up these recent gains.Whether it can burst through its prior highs near $59 and run to $72 is currently unknown. But if it wants any shot at doing even that, it needs to hold over some of these key levels that it just cleared.Here's what to watch: $48 and prior downtrend resistance (blue line No. 2). According to the RSI, CGC stock is not overbought even after its strong rally over the past few days. According to its MACD reading, momentum is returning to the bulls' favor and could have a lot of upside going forward. Ideally we would see a continuation higher or consolidation near current levels, before a pullback to $48 that holds as support.If $48 soon acts as resistance, bulls need to see the backside of prior downtrend resistance act as support. Bottom Line on Canopy Growth StockIf investors feel that there is momentum in cannabis stocks, then CGC stock is certainly one of the top considerations to ride that wave. In the end though, this is a speculative group and investors have to remember that going forward. This isn't some blue chip stock with a reasonable valuation and strong cash flows.Last quarter (Q3, fiscal 2019), the company had $60.8 million in revenue. That's roughly the same total as it did for all of fiscal 2018. Clearly the growth is very impressive, but we're talking about a company that has consensus expectations for $176 million in sales this year vs. a market cap of more than $16 billion.Granted, estimates call for more than $600 million in sales in fiscal 2020 (which starts in one quarter), but this is still a lofty valuation. That's why M&A deals (such as with Constellation) are so important. It puts billions of dollars into Canopy's coffers, allowing it run its operations and make deals like it did for ARCGF. * 10 High-Yielding Dividend Stocks That Won't Wilt It's a speculative group, but Canopy is among the best in the business.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post Is Canopy Growth Stock Set to Break Out and Rally 90%? appeared first on InvestorPlace.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
Canopy Growth's (CGC) announced intention to purchase Acreage Holdings dominated headlines last week. In fact, it dominated headlines so much that many investors may have missed the note that Cowen's Vivien Azer put regarding Canopy competitor Aurora Cannabis (ACB).That would be a crying shame -- because in Azer's estimation, there may actually be more reasons to buy Aurora Cannabis stock, than Canopy.Let's run down the list.A race to scaleFor all that investors have been fascinated by the growth of the marijuana industry for the past several years, the fact remains: This is still a very young industry, and in young industries like this one, the first challenge is generally to scale up quickly, grab market share, drive out competition -- so that by the time the industry matures, they'll be able to keep more profits for themselves.Aurora Cannabis aims to win this race.Already, Aurora says it's ahead of its targeted annual rate of 120,000 kilograms of annual marijuana production capacity for this time, this year. Annualized, management says it's now producing at something more like a 150,000 kg-per-year rate.150,000 kg -- and growing. As Azer reports, Aurora is expanding square footage at its Aurora Sun facility to 1.6 mm square feet so as to add 230,000 kg in annual capacity. Production rates at the Aurora Sky facility are also on the upswing, and in consequence, Aurora management says it is raising its targeted production capacity by 25%, from 500,000 kg to 625,000 kg annual production -- a goal it hopes to reach by mid-2020.To put that in perspective, Canopy Growth says it is looking to produce only 400,000 kg by mid-next year -- less than two-thirds of Aurora's target -- albeit Azer notes that Canopy's target may be "conservative."Cost cutsWhy expand production capacity so much? To create greater supply, of course, to serve the market -- but also to win production efficiencies derived from scale. Aurora Cannabis believes that once it reaches its targeted level of production, it should be able to cut cash costs nearly in half, from about C$1.92 per gram of marijuana produced currently to under C$1 per gram.MarginsGross margins equaling sales minus the cost of the goods sold, such cost cuts should be very good news for Aurora Cannabis' profit margins.Already, Azer says Aurora boasts 61% trailing gross margins, or twice the 29% margins that Canopy produced over the last 12 months -- and Aurora's margins have exceeded 50% for the past eight straight quarters. With lower costs, the analyst estimates Aurora could grow its gross margin to as much as 70%, the best rate in the industry.What to expect on earningsGranted, Aurora's net margins remain negative, but perhaps not for long. Most analysts expect Aurora to turn profitable as early as next year. As for this year, Aurora expects to have 25,000 kg of cannabis produced, packaged, and ready for sale in fiscal Q4 (ending in June). Azer says its own "conservative" estimate is that Aurora won't sell more than 16,000 kg this quarter -- but will be happy to be proven wrong, as this would mean only "upside to our forecasts."For an analyst that rates Aurora Cannabis "outperform," that's a good thing.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on ACB: * How Aurora Cannabis (ACB) Stock Gets to $11 * Aurora Cannabis (ACB) Stock Is in Position for Another Bullish Leg * Aurora Cannabis: Flooding the Cannabis Market with More Supply More recent articles from Smarter Analyst: * Cannabis Stock Health & Recreation (HRVSF) Is Very Appealing Based on Long-Term Bullish Fundamentals * Cannabis Stock Canopy Growth (CGC) Stands to Gain from Potential Legalization in the US * With Two Days to Go Before Amazon (AMZN) Earnings, this Top Analyst Weighs in on the Stock * Should You Count on Facebook (FB) Earnings to Push the Stock Higher? Top Analyst Weighs In
In 2019, investors have been looking for stocks to buy -- not stocks to sell. A broad market selloff toward the end of last year admittedly created some bargains. Key sectors like energy, semiconductors and software offered their share of bargains.This year obviously has been very different. The S&P 500 has gained 16%, and the gains have been spread across the entire U.S. equity market. Among stocks with a market capitalization over $300 million, just 559 -- or 16% -- are down year-to-date. A greater number of those stocks -- 771 -- have gained at least 30%.In that group are some stocks that simply became too cheap amid the fourth quarter plunge. Others have soared thanks to strong performance. But there are more than a few that seem to be benefiting from market optimism -- and not performing nearly as well as their share prices would suggest.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 High-Yielding Dividend Stocks That Won't Wilt These 10 stocks all fit that bill. All have gained at least 30% so far this year, yet for various reasons, seem like stocks to sell at the moment. And when the current market strength inevitably starts to fade, these 10 stocks may be the first to fall. Shopify (SHOP)Source: Shopify via FlickrFew stocks reflect the reversal in market sentiment more than e-commerce platform Shopify (NYSE:SHOP). In late December, SHOP stock touched a nine-month low after losing 25% of its market value in just seven sessions. Since then, however, SHOP has gained nearly 90%, adding some $11 billion in market value in the process.And yet, as I wrote earlier this month, the news surrounding Shopify stock really hasn't been that good. 2019 guidance was seen as modestly disappointing. Competition from Facebook (NASDAQ:FB), Square (NYSE:SQ), and privately held Mailchimp seems to be intensifying.Analysts haven't even been able to keep up: the average price target of $189 suggests 16% downside. Yet SHOP keeps marching higher.There is a bull case here, admittedly, and a valuable business. But at 20x+ revenue and 250x 2020 EPS estimates, perfection looks priced in - and then some. I'd call it a stock to sell. Aurora Cannabis (ACB)Source: Shutterstock Marijuana stocks like Aurora Cannabis (NYSE:ACB) similarly have benefited from the stronger market, and the return of the 'risk-on' trade. ACB stock has gained 86% in 2019. Canopy Growth (NYSE:CGC) is up 80%, and Cronos Group (NASDAQ:CRON) 62%. Only Tilray (NASDAQ:TLRY) has been left out.The gains across the board seem a bit much. Marijuana companies obviously have an enormous opportunity; but there's a long road ahead. Valuations are getting stretched again. Aurora's aggressive strategy is high-risk (if admittedly high-reward), and the steady issuance of stock and debt only adds to that risk. * 7 Small-Cap Growth ETFs For Adventurous Investors To be sure, ACB has promise, as does the sector. But the worry with Aurora Cannabis isn't so much that the company is going to blow up -- or even disappoint -- but rather that the pot industry on the whole is getting overvalued. And with ACB one of the biggest gainers on the way up, it could be one of the larger losers on the way down. Snap (SNAP)Source: Shutterstock Among stocks with a market capitalization above $10 billion, no stock has done better than Snap (NYSE:SNAP) in 2019. It's not even close: SNAP stock has risen 110%, thirty points better than second-place CGC.As I wrote this month, the optimism makes some sense. Execution looks better, and Snap has years of benefits ahead simply from better monetizing its existing users.At the same time, however, the 100%+ gains make SNAP stock look awfully stretched. And the existing user base simply isn't enough -- even if revenue per user continues to rise. This remains a significantly unprofitable company valued at $15 billion. Certainly, there's no shortage of those types of stocks to sell in this market -- but there aren't any others that have doubled in less than four months. Carvana (CVNA)Source: Carvana Used-car retailer Carvana (NYSE:CVNA) has become one of the bigger battleground stocks in the market. The company's online model threatens to disrupt the entire industry, which has brought buyers into CVNA stock. Indeed, Josh Enomoto this month called CVNA one of the 7 best long-term stocks to buy and hold, not long after Luce Emerson detailed the bull case on this site.And there is an intriguing aspect to Carvana's model. But there are also a lot of losses: EBITDA margin for 2018 was negative 10%, with guidance for -3.5% to -5.5% in 2019. Even long-term targets of 8-13.5% suggest only modest profitability.As a result, CVNA might have its share of bulls, but it also has a heavy short interest. Some 56% of the admittedly thin float is sold short. Those shorts have been squeezed so far this year, likely contributing to the 100% gains in Carvana shares so far this year. But shorts make some good points: most notably that Carvana may be trying to take share in what is likely to be a declining market going forward. * 7 Digital Ad Stocks That Deserve Your Attention Right Now Meanwhile, CVNA may be one of the best performers in 2019 -- but it was one of the worst performers at the end of last year, losing more than half its value in a matter of months. If the market stumbles at all, Carvana stock probably takes a tumble. 10 Soaring Stocks to Sell: Wayfair (W)Source: Shutterstock There's an interesting parallel between Carvana and online furniture retailer Wayfair (NYSE:W). Both companies are trying to disrupt industries based on in-person selling through online-focused models. Neither company is profitable. Shorts are targeting both stocks, arguing that growth is being bought through below-market pricing that simply isn't sustainable.And both stocks have soared in 2019 after falling quickly last year. W stock hasn't quite matched that of its automotive peer, but it's gained a handsome 64% so far this year.Here, too, the gains look like too much. Given how cyclical the furniture industry is, investors truly have to trust the economy to assume that growth will continue. (That's true for Carvana as well, by the way.) And in year ten of an economic expansion, that seems dangerous. Cyclical stocks in the rest of the market are being valued as if earnings are near a peak. What does that mean for a cyclical company with no earnings at all? Conagra Brands (CAG)Source: Shutterstock Four months ago, Conagra Brands (NYSE:CAG) seemed to be in disarray. Investors were fleeing CAG stock, which hit a six-year low in late December. A cut to 2019 guidance raised questions about growth, and even Conagra's ability to service debt raised in its acquisition of Pinnacle Foods.Sentiment toward the CPG (consumer packaged goods) sector didn't help. The plunge at industry leader Kraft Heinz (NASDAQ:KHC) cast a shadow over the entire industry. Consumer tastes simply seemed to be moving away from companies like Conagra and Kraft Heinz.That sentiment seems to have reversed -- at least in the case of Conagra. CAG stock has gained 44% so far this year. (KHC stock continues to fall, however.) A strong Q3 earnings report certainly helped the cause. But the broader worries here hardly seem assuaged. Grocery store customers like Kroger (NYSE:KR) still are struggling, and still trying to push private-label items in a bid to protect margins. Brands like Chef Boyardee, frozen dinner nameplate Marie Callender's, and Slim Jim don't seem likely to drive much growth, particularly among millennials. * 7 Strong Buy Stocks the Street Loves And while investors cheered Q3 results, Conagra cut full-year organic sales growth guidance to just 1%. That's simply not enough to drive profit growth -- or to support even a seemingly modest 15x P/E multiple. Unless that growth improves, at some point the fears that dogged CAG just a few months ago are likely to return. Anheuser-Busch InBev (BUD)Source: Paul Sableman via FlickrKHC and CAG weren't the only consumer stocks to plunge in 2018. Anheuser-Busch InBev (NYSE:BUD) stock fell 39% in 2018. Slowing growth, debt worries, and a halved dividend drove the selling pressure.Here too, a decent but not spectacular earnings report has helped the cause. BUD has bounced sharply in 2019, rising 36%. But the gains seem like far too much. The problems dogging the stock haven't gone anywhere. Beer demand could take a hit from cannabis legalization. Sales already are slowing: shares of other beer plays like Boston Beer (NYSE:SAM) and Constellation Brands (NYSE:STZ,STZ.B) have struggled as a result. And Anheuser-Busch's debt load, even with the dividend cut, remains a concern.There is a case that BUD fell too far toward the end of 2018. This remains a global company with hugely valuable brands. But even if BUD was too cheap at the end of 2018, the current price suggests investors have forgotten why the sell-off even happened. Apple (AAPL)Source: Apple In the near term, Apple (NASDAQ:AAPL) still may have more room to run. The stock still sits 12% off all-time highs reached in October. AAPL stock only has a few points to go to return to the $1 trillion market capitalization it first reached in August. The company still has a huge cash hoard for buybacks, and a 16x forward P/E multiple hardly seems aggressive.That said, there are multiple concerns here. For all the hype about the services business, the iPhone still drives over 60% of sales, and it's headed in the wrong direction. Replacement cycles are lengthening, pricing is probably maxed out, and the company still has a problem in China. The recent settlement with Qualcomm (NASDAQ:QCOM) doesn't help the cause, either. * Why These Are the Top 2 Pot Stocks to Buy Right Now This still seems like a company whose earnings likely have peaked, and that suggests AAPL stock could be, and should be, cheaper. Indeed, that's how investors saw it just a few months ago -- and while AAPL stock has gained 30% this year, it's hard to see what has changed their mind so quickly. Under Armour (UAA)Source: Shutterstock Back in December, Under Armour (NYSE:UA,UAA) announced five-year targets at its Investor Day. Investors clearly were disappointed: UAA stock plunged on the news.Under Armour stock now has gained 37% from December lows, and the obvious question is: why? Q4 earnings were in line. Guidance was within expectations. Commentary from retail partners about holiday sales hardly seemed particularly bullish for UAA. Nothing really has changed since December - except for the Under Armour share price.UAA now trades at 45x next year's earnings. Margins should expand, but they're thin to begin with. Revenue growth isn't good enough. And competition from Nike (NYSE:NKE) and adidas (OTCMKTS:ADDYY) isn't going anywhere.At this point, investors are valuing Under Armour as if management is being too pessimistic. There's very little in the company's operating history to suggest that will be the case. GoPro (GPRO)Source: GoPro Even with a pullback in recent sessions, GoPro (NASDAQ:GPRO) has gained 48% so far this year. Like so many stocks to sell on this list -- and in this market -- the gains are amplified by just far the stock had fallen. GPRO touched an all-time low in December.There is some hope for a turnaround, as I detailed last year. But I wrote this week that even some turnaround looks priced in. GoPro dominates its markets, which is a problem, because it can't take share. Cost-cutting has run its course. This looks like a company unlikely to grow earnings much, if at all -- yet it's again priced for growth. * 10 High-Yielding Dividend Stocks That Won't Wilt More broadly, this is a company that's disappointed before. But like so many stocks on this list, investors seem to be forgetting -- or ignoring -- the risks, and focusing only on the potential rewards. At this point, with GPRO stock, even those rewards don't seem likely to result in much more in the way of upside.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post 10 Stocks to Sell Before They Give Back 2019 Gains appeared first on InvestorPlace.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
CALGARY , April 23, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HTDEF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced approximately $441,000 in systemwide gross revenues ("Sales") from April 19th to 21st, 2019 , which is a 234% increase over the $132,000 reported for the same three-day period in 2018. This record result was generated from the Company's 13 Canna Cabana-branded stores including the two partnered Ontario locations in Hamilton and Sudbury that opened on April 20th , from its 13 Smoker's Corner locations across Canada , as well as from the Grasscity, Famous Brandz and Smoker's Corner e-commerce websites.
This marijuana stock has been initiated at, or downgraded to, the equivalent of a sell rating four times in less than two months.
CORAL GABLES, FL / ACCESSWIRE / April 22, 2019 / Investors should be paying close attention to the cannabis industry right now. Currently, recreational marijuana is now legal in 10 US states & medical marijuana is legal in 33 US States. Today we are highlighting: Canopy Growth Corporation (CGC) / (TSX:WEED.TO), Aphria Inc. (APHA), Aurora Cannabis Inc. (ACB), Leafbuyer Technologies, Inc. (LBUY).
Aurora Cannabis (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P) has signed a binding letter of intent with Hempco Food and Fiber (TSX-V: HEMP) to acquire all of the issued and outstanding common shares of Hempco. Under the deal, Aurora will pay C$1.04 per share, payable in common shares, totaling around C$63.4 million. Currently, Aurora owns about […]The post Aurora Cannabis Agrees to Acquire All Hempco Shares appeared first on Market Exclusive.
Ever since the cannabis craze hit Wall Street back in mid-2018, I've been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:CGC). The logic is simple: In addition to being the biggest player in the industry, CGC stock has long had one thing that no other cannabis company has -- $4 billion in cash from Constellation Brands (NYSE:STZ).Source: Shutterstock That $4 billion gives Canopy unprecedented visibility into being one of the industry's long-term winners through early, aggressive, and large investments. As such, I have consistently reasoned that CGC stock belongs in every cannabis-related portfolio.This bull thesis got a big boost in mid-April. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor those who don't follow this industry closely, that's a big deal. Canopy is the star player in the legal Canadian cannabis market. But the Canadian market is peanuts. The big deal here is the U.S. market. Depending on who you ask, that market is about tenfold the size of the Canadian market.Thus, the big question for Canopy and other Canadian pot stocks is whether or not these companies can replicate their success in the U.S. * 7 Strong Buy Stocks the Street Loves Canopy just answered that question in emphatic fashion, and the market is reacting favorably. CGC stock popped roughly 10% on the news.In the big picture, thanks to a $4 billion early investment from Constellation Brands, Canopy has given itself unprecedented visibility into being a long-term cannabis market leader. Right now, following the Acreage deal, that visibility is as strong as ever. Consequently, the long-term bull thesis for CGC is likewise as strong as ever. The Acreage Acquisition Is Big NewsThere's a reason CGC popped 10% in response to the company agreeing to acquire Acreage. In plain English, it positions the company to fully capitalize on the $100 billion U.S. cannabis market from the onset.First, some context. The whole Wall Street cannabis craze has been largely centered around one thing: the nationwide legalization of cannabis in Canada in late 2018. Roughly speaking, that single catalyst turned the big four Canadian pot stocks -- Canopy, Aurora (NYSE:ACB), Tilray (NASDAQ:TLRY) and Cronos (NASDAQ:CRON) -- from relatively unknown companies to Wall Street household names with multi-billion dollar market caps.But, while Canadian market legalization was the catalyst, it wasn't the prize. The prize here is the U.S. market, which most estimates put at a $100 billion opportunity, versus $10 billion in Canada. The consensus thesis is that, with cannabis fully legal throughout Canada and hemp legal throughout the U.S., it's only a matter of time before cannabis is fully legal across the entire U.S. The big question is whether or not Canadian cannabis giants like Canopy will be able to capitalize on the big U.S. opportunity when it comes knocking.Canopy just answered that question. By agreeing to acquire Acreage -- a major U.S. cannabis operator with dozens of dispensaries and cultivation sites across 20 states -- Canopy has positioned itself to capitalize on the $100 billion U.S. cannabis market opportunity from the onset. That is, as soon as cannabis is fully legal across the U.S., Canopy will be everywhere through Acreage -- and ready to dominate the U.S. market like it's dominated the Canadian market.That's a big deal. Indeed, it paves the path for CGC to head materially higher in a long-term window. Canopy Growth Stock Has Long-Term UpsideMy long-term bull thesis on Canopy Growth stock is that, if this company can successfully maintain its leadership position as the cannabis industry goes global and matures, then this is a $100 billion company in the making. With more visibility than ever to U.S. market domination, that long-term bull thesis looks about as good as ever.The details of my analysis behind the $100 billion number can be found here. But the short recap is pretty easy to understand. At scale, given current consumption trends, the recreational cannabis market could one day be as big as the alcoholic beverage and tobacco markets. What's more, if you consider the medical opportunity, then the aggregate global cannabis market will easily one day be as big as, if not bigger than, the alcoholic beverage and tobacco markets.The top dogs in those two industries have $100 billion-plus market caps. Witness Anheuser-Busch (NYSE:BUD) or Altira (NYSE:MO). Thus, it's only reasonable to assume that the top dogs in the global cannabis industry at scale will be $100 billion-plus companies too.Given its early leadership position, huge financial resources, aggressive management team, large growing capacity, and global distribution network, Canopy has all the tools necessary to turn into a top dog in the global cannabis industry in a decade. Now, Canopy also has visibility to be a top dog in the U.S. market. Thus, this company continues to take steps towards securing global leadership.So long as the company remains on that path, CGC stock will remain on an uptrend towards a $100 billion valuation. * 10 Dividend Growth Stocks You Can't Miss Bottom Line on CGC StockThere are a lot of pot stocks out there, but none of them have as much long-term visibility as Canopy Growth. Given this, if you're buying into the cannabis industry with a multi-year horizon, CGC stock is the best pick in the industry, without question.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post This Is Why Canopy Growth Is the Best Pot Stock appeared first on InvestorPlace.
HENDERSON, NV / ACCESSWIRE / April 22, 2019 / Bank of America analyst, Christopher Carey, has begun coverage of the cannabis industry with a note Wednesday naming Hexo Corp. (HEXO) as the firm's top pick ...
EDMONTON , April 18, 2019 /CNW/ - Calling all Canadian budtenders! Aurora Cannabis is kicking off the search for Canada's Top Budmaster ™ through a national competition that will recognize cannabis professionals across the country who are guiding consumers as they navigate the new world of legal cannabis. Through a series of skills-based and knowledge-testing events, as well as through digital competitions, Canada's budtender community will be able to demonstrate their expertise in cultivar characteristics and histories, product categories and formats, exceptional customer service, and must also showcase how they contribute to the community and culture. As Canada's first legal 420 holiday approaches, it's time to recognize the women and men in cannabis retail stores who educate consumers every day.